Decision Resources Group (previously known as Decision Resources, Inc.), one of the world's leading research and advisory firms focusing on healthcare insights and analysis, announced today that it acquired PharmaStrat, the leading consulting and market research services firm focused on issues related to reimbursement and organized customer segments for biopharmaceutical manufacturers. The acquisition of Flemington, N.J.-based PharmaStrat by Burlington, Mass.-based Decision Resources Group will result in a significant expansion of Decision Resources Group's market access capabilities.
PharmaStrat's focus on innovative methodological approaches, the integration of those approaches and multi-stakeholder insights sets the firm apart in the industry.
"We are excited to continue our growth as a Decision Resources Group company," said Phil Patrick, founder of PharmaStrat. "We look forward to continuing to expand our portfolio of client offerings by leveraging the rich intellectual capital at Decision Resources Group."
Reimbursement issues and customer segmentation are high priorities for biopharmaceutical organizations and, as markets get more competitive, guidance on these issues from industry-leading experts is critical.
"PharmaStrat is an important acquisition in Decision Resources Group's overall strategy to expand our market access capabilities and offer our clients the most innovative, high-value advisory solutions," said Peter Hoenigsberg, CEO of Decision Resources Group. "Positioning drug brands in a way to maximize reimbursement has become quite possibly the most significant issue for pharmaceutical companies today. PharmaStrat brings to Decision Resources Group unparalleled expertise in this area."
Rethinking mental health research through AI-driven simulations